Honors & Awards

  • Positive comment of “Benkafadar N et al., EMBO Molecular Medicine” in "News & Views”, EMBO Molecular Medicine, 9: 4-6, by Nonnekens J and Hoeijmakers JH (01/2017)
  • Publication of “Cancers & audition: The end of the double penalty”, Languedoc-Roussillon INSERM Newspaper (12/2016)
  • Best Poster Award, Ageing 2016 Meeting (06/2016)
  • Graduate fellowship program, Foundation of the Future for Medical Research (10/2014)

Professional Education

  • Doctor of Philosophy, Universite De Montpellier (2018)
  • Master of Health and Science, Universite De Montpellier (2014)
  • Doctor of Pharmacy, Universite De Constantine (2012)


  • Nesrine Benkafadar, Julien Menardo, Jean-Luc Puel and Jing Wang. " Patent WO2017125429A1 The use of a temporary inhibitor of p53 for preventing or reducing cancer relapse", Institut National de la Santé et de la Recherche Médicale (INSERM) - Universite De Montpellier, Jul 27, 2017


All Publications

  • New Strategies for Improving the Quality of Life of Cancer Survivors: Reversible p53 Inhibition Journal of Cancer Science & Therapy Benkafadar, N., Coyat, C., Lloyd, R., Puel , J., Wang, J. 2017; 9(6): 490-491
  • Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy. EMBO molecular medicine Benkafadar, N., Menardo, J., Bourien, J., Nouvian, R., François, F., Decaudin, D., Maiorano, D., Puel, J., Wang, J. 2017; 9 (1): 7-26


    Cisplatin is a widely used chemotherapy drug, despite its significant ototoxic side effects. To date, the mechanism of cisplatin-induced ototoxicity remains unclear, and hearing preservation during cisplatin-based chemotherapy in patients is lacking. We found activation of the ATM-Chk2-p53 pathway to be a major determinant of cisplatin ototoxicity. However, prevention of cisplatin-induced ototoxicity is hampered by opposite effects of ATM activation upon sensory hair cells: promoting both outer hair cell death and inner hair cell survival. Encouragingly, however, genetic or pharmacological ablation of p53 substantially attenuated cochlear cell apoptosis, thus preserving hearing. Importantly, systemic administration of a p53 inhibitor in mice bearing patient-derived triple-negative breast cancer protected auditory function, without compromising the anti-tumor efficacy of cisplatin. Altogether, these findings highlight a novel and effective strategy for hearing protection in cisplatin-based chemotherapy.

    View details for DOI 10.15252/emmm.201606230

    View details for PubMedID 27794029

    View details for PubMedCentralID PMC5210089

  • Impairment of Visual Function and Retinal ER Stress Activation in Wfs1-Deficient Mice PLOS ON Bonnet Wersinger, D., Benkafadar, N., Jagodzinska, J., Hamel, C., Tanizawa, Y., Lenaers, G., Delettre, C. 2014; 9 (5)